Question 1

What is combined oxidative phosphorylation deficiency 43?

Accepted Answer

Combined oxidative phosphorylation deficiency 43 is a multisystem disorder that primarily affects energy production and growth in early infancy. It is associated with pathogenic variants in the TIMM22 gene, which plays a critical role in mitochondrial protein import. Affected individuals typically present with symptoms soon after birth, including feeding difficulties and low muscle tone. Precise prevalence estimates are not well established, and the rarity of this condition means that it is still under detailed investigation.

Question 2

What are the symptoms of combined oxidative phosphorylation deficiency 43?

Accepted Answer

Individuals with this condition almost invariably exhibit a number of characteristic clinical features. Notable findings include acetabular dysplasia, being small for gestational age, intrauterine growth retardation, and projectile vomiting. Additionally, patients often show elevated creatine kinase levels, delayed central nervous system myelination, and decreased activity in several mitochondrial complexes, accompanied by increased circulating lactate levels and gastroesophageal reflux. Feeding difficulties in infancy and neonatal hypotonia are consistently reported, though not all individuals experience every feature and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation deficiency 43?

Accepted Answer

Combined oxidative phosphorylation deficiency 43 is caused by pathogenic variants in the TIMM22 gene. TIMM22 is essential for the proper import of proteins into mitochondria, and disruption of its function compromises cellular energy production. The condition is inherited in an autosomal recessive pattern, meaning that affected individuals inherit two altered copies of the gene, one from each carrier parent. Genetic counseling is recommended for families to better understand recurrence risks and implications for family planning. Associated genes include TIMM22.

Question 4

How is combined oxidative phosphorylation deficiency 43 inherited?

Accepted Answer

combined oxidative phosphorylation deficiency 43 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How is combined oxidative phosphorylation deficiency 43 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the TIMM22 gene. In addition to genetic testing, a comprehensive clinical evaluation is important, particularly when there is a history of prenatal growth retardation, neonatal hypotonia, feeding difficulties, and biochemical abnormalities such as elevated lactate and creatine kinase levels. Because these features can be seen in other conditions, genetic testing remains essential to distinguish this condition from others with overlapping clinical presentations.

Question 6

Are there treatments for combined oxidative phosphorylation deficiency 43?

Accepted Answer

Currently, management focuses on supportive care and symptom management, as there are no FDA-approved treatments specifically for combined oxidative phosphorylation deficiency 43. Treatment is tailored to the individual and typically involves a multidisciplinary team that may include specialists in metabolic disorders, neurology, and nutrition to address feeding difficulties, metabolic imbalances, and neuromuscular challenges. Patients should discuss treatment options with their healthcare team to determine which supportive therapies and interventions may be appropriate, and genetic counseling is recommended for additional guidance.

Question 7

What complications can arise from combined oxidative phosphorylation deficiency 43?

Accepted Answer

Complications from combined oxidative phosphorylation deficiency 43 can include significant challenges in early life, such as feeding difficulties and low muscle tone. Patients may also experience delayed development and issues related to energy production, which can affect their growth and overall health. Because symptoms and severity can vary widely, ongoing monitoring and supportive care are essential to manage these complications.

Question 8

How does combined oxidative phosphorylation deficiency 43 affect daily life for patients and families?

Accepted Answer

Daily life for patients with combined oxidative phosphorylation deficiency 43 can be challenging due to feeding difficulties and the need for specialized care. Families may need to work closely with a multidisciplinary team, including specialists in nutrition and neurology, to address these issues. Supportive therapies and interventions can help improve quality of life, but families should be prepared for ongoing management and adjustments as their child grows.

Question 9

What is the prognosis for individuals with combined oxidative phosphorylation deficiency 43?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation deficiency 43 varies widely based on the severity of symptoms and the age at which they are diagnosed. While many patients benefit from supportive therapies that improve their quality of life, the condition is lifelong and can lead to significant challenges. Ongoing care and connection with specialists can help families navigate these challenges and improve outcomes over time.

Question 10

What specific symptoms should families be aware of in combined oxidative phosphorylation deficiency 43?

Accepted Answer

Families should be aware of several specific symptoms associated with combined oxidative phosphorylation deficiency 43, including feeding difficulties, low muscle tone, and projectile vomiting. Other notable symptoms include being small for gestational age and intrauterine growth retardation. Elevated creatine kinase levels and increased circulating lactate can also be present, but not every individual will experience all symptoms, and their severity can vary.

Research Type	Count	% of Total
Laboratory research	12	46%

Kisho

combined oxidative phosphorylation deficiency 43

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

Recent Publications

combined oxidative phosphorylation deficiency 43

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation deficiency 43?

What are the symptoms of combined oxidative phosphorylation deficiency 43?

What causes combined oxidative phosphorylation deficiency 43?

How is combined oxidative phosphorylation deficiency 43 inherited?

How is combined oxidative phosphorylation deficiency 43 diagnosed?

Are there treatments for combined oxidative phosphorylation deficiency 43?

What complications can arise from combined oxidative phosphorylation deficiency 43?

How does combined oxidative phosphorylation deficiency 43 affect daily life for patients and families?

What is the prognosis for individuals with combined oxidative phosphorylation deficiency 43?

What specific symptoms should families be aware of in combined oxidative phosphorylation deficiency 43?

Explore clinical features

Recent Publications